Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us now| Characteristic | Percentage of the population |
|---|---|
| 2022-2023* | 3.23% |
| 2021–2022* | 3.23% |
| 2020–2021* | 3.23% |
| 2019–2020 | 3.25% |
| 2018–2019 | 3.27% |
| 2017–2018 | 3.29% |
| 2016–2017 | 3.31% |
| 2015–2016 | 3.34% |
| 2014–2015 | 3.37% |
| 2013–2014 | 3.36% |
| 2012–2013 | 3.39% |
| 2011–2012 | 3.43% |
| 2010–2011 | 3.47% |
| 2009–2010 | 3.51% |
| 2008–2009 | 3.53% |
| 2007–2008 | 3.51% |
| 2006–2007 | 3.54% |
| 2005–2006 | 3.56% |
| 2004–2005 | 3.57% |
| 2003–2004 | 3.57% |
| 2002–2003 | 3.53% |
| 2001–2002 | 3.48% |
| 2000–2001 | 3.37% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Source
Release date
October 2024
More information
Region
Canada
Survey time period
2000 to 2023
Age group
40 years and older
Supplementary notes
Rates are age-adjusted.
Adapted from the Canadian Chronic Disease Surveillance System (CCDSS). This does not constitute an endorsement by the Government of Canada of this product.
The source gives the following note: "Many CCDSS measures, such as chronic disease incidence, were influenced by the COVID-19 pandemic. Changes in such measures may be driven by multiple factors, including (but not limited to) differences in healthcare seeking behaviour, the availability and use of healthcare services, as well as true changes in health status. As such, CCDSS measures should be used cautiously when making inferences about population health during the COVID-19 pandemic. Guidance for data users on examining the impacts of the COVID-19 pandemic on CCDSS measures can be accessed below."
Citation formats
